Literature DB >> 4354635

The mode of action and clinical use of spirolactones.

A Manitius, T Suchecki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4354635

Source DB:  PubMed          Journal:  Mater Med Pol        ISSN: 0025-5246


× No keyword cloud information.
  5 in total

1.  Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

Authors:  L E Ramsay; P Hessian; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

2.  Canrenone--the principal active metabolite of spironolactone?

Authors:  L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Paradoxical potassium excretion in response to aldosterone antagonists.

Authors:  L E Ramsay; I R Harrison; J R Shelton; M J Tidd
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

4.  The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.

Authors:  L E Ramsay; J R Shelton; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

5.  Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.

Authors:  D Levine; L Ramsay; R Auty; R Branch; M Tidd
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.